검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Hydroxychloroquine (Hydroxychloroquine) Shanghai Juncell Therapeutics·Advanced Breast Cancer ORR 75%·t½ 40 h | |||
|---|---|---|---|---|
Overview Program | Ebglyss (lebrikizumab) | Hydroxychloroquine | Dupixent (dupilumab) | Cyclosporine |
Overview Company | Eli Lilly | Shanghai Juncell Therapeutics | Sanofi / Regeneron | Novartis |
Overview Modality | ANTIBODY | ADC | ANTIBODY | ANTIBODY |
Overview Target | IL-13 | Advanced Breast Cancer | IL-4Rα | FRα |
Overview Indication | Atopic dermatitis | Psoriasis; Atopic Dermatitis | Atopic dermatitis, asthma, CRSwNP, EoE | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | ACTIVE | APPROVED | ACTIVE |
MoA Mechanism | Anti-IL-13 monoclonal antibody | targeting mitochondrial pathway | targeting specific inflammatory pathway | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling |
MoA Biomarker | EASI, IGA | biomarkers capable of identifying subclinical damage remain incompletely defined | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat |
PK/PD Half-life | 24.5 h | 40 h | — | — |
PK/PD Species | Mouse | Rat | — | Mouse, carbamazepine, cyclosporine, and quinidine. |
PK/PD Animal (cat.) | Mouse | Rat, In vitro | In vitro | Mouse |
PK/PD Experiment | pharmacokinetic | PD | PD | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse | Rat | Mouse | Mouse, Rat, Hamster, carbamazepine, cyclosporine, and quinidine. |
Toxicology Animal (cat.) | NHP | Unknown | Mouse | Mouse, Rat |
Toxicology Major finding | — | Hepatotoxicity was reported in patients with porphyria cutanea tarda ( 5 | — | — |
Clinical Primary efficacy | ORR 75% | ORR 75% | ORR 0.45% | ORR 35% |
Clinical ORR | EASI-75 ~59% (ADvocate) | 75% | -0.45 | 35% |
Clinical PFS | — | 424 | — | — |
Clinical OS | — | 788 | — | — |
Clinical Result source | ADvocate | ClinicalTrials.gov NCT01006369 | ClinicalTrials.gov NCT02912468 | ClinicalTrials.gov NCT00104858 |
Clinical Data Tier / Score | S · 91 | B · 74 | C · 65 | C · 51 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Hydroxychloroquine (Hydroxychloroquine) Shanghai Juncell Therapeutics·Advanced Breast Cancer ORR 75%·t½ 40 h | |||
|---|---|---|---|---|
Overview Program | Ebglyss (lebrikizumab) | Hydroxychloroquine | Dupixent (dupilumab) | Cyclosporine |
Overview Company | Eli Lilly | Shanghai Juncell Therapeutics | Sanofi / Regeneron | Novartis |
Overview Modality | ANTIBODY | ADC | ANTIBODY | ANTIBODY |
Overview Target | IL-13 | Advanced Breast Cancer | IL-4Rα | FRα |
Overview Indication | Atopic dermatitis | Psoriasis; Atopic Dermatitis | Atopic dermatitis, asthma, CRSwNP, EoE | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | ACTIVE | APPROVED | ACTIVE |
MoA Mechanism | Anti-IL-13 monoclonal antibody | targeting mitochondrial pathway | targeting specific inflammatory pathway | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling |
MoA Biomarker | EASI, IGA | biomarkers capable of identifying subclinical damage remain incompletely defined | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat |
PK/PD Half-life | 24.5 h | 40 h | — | — |
PK/PD Species | Mouse | Rat | — | Mouse, carbamazepine, cyclosporine, and quinidine. |
PK/PD Animal (cat.) | Mouse | Rat, In vitro | In vitro | Mouse |
PK/PD Experiment | pharmacokinetic | PD | PD | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse | Rat | Mouse | Mouse, Rat, Hamster, carbamazepine, cyclosporine, and quinidine. |
Toxicology Animal (cat.) | NHP | Unknown | Mouse | Mouse, Rat |
Toxicology Major finding | — | Hepatotoxicity was reported in patients with porphyria cutanea tarda ( 5 | — | — |
Clinical Primary efficacy | ORR 75% | ORR 75% | ORR 0.45% | ORR 35% |
Clinical ORR | EASI-75 ~59% (ADvocate) | 75% | -0.45 | 35% |
Clinical PFS | — | 424 | — | — |
Clinical OS | — | 788 | — | — |
Clinical Result source | ADvocate | ClinicalTrials.gov NCT01006369 | ClinicalTrials.gov NCT02912468 | ClinicalTrials.gov NCT00104858 |
Clinical Data Tier / Score | S · 91 | B · 74 | C · 65 | C · 51 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교